XRCC6 (ku70) is a direct target of the newly identified PIM1, and a study has demonstrated that PIM1 phosphorylates KU70 and initiates DNA repair signalling in pulmonary artery smooth muscle cells (PAH-PASMCs) in pulmonary arterial hypertension (PAH) rat models; therefore, PIM1 inhibitors represent a therapeutic option for patients with PAH [19]. This evidence concerns the gene PIM1 and pulmonary arterial hypertension.